282 related articles for article (PubMed ID: 21917729)
1. Cell-cycle regulator Cks1 promotes hepatocellular carcinoma by supporting NF-κB-dependent expression of interleukin-8.
Lee EK; Kim DG; Kim JS; Yoon Y
Cancer Res; 2011 Nov; 71(21):6827-35. PubMed ID: 21917729
[TBL] [Abstract][Full Text] [Related]
2. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis.
Calvisi DF; Ladu S; Pinna F; Frau M; Tomasi ML; Sini M; Simile MM; Bonelli P; Muroni MR; Seddaiu MA; Lim DS; Feo F; Pascale RM
Gastroenterology; 2009 Nov; 137(5):1816-26.e1-10. PubMed ID: 19686743
[TBL] [Abstract][Full Text] [Related]
3. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.
Bhatt KV; Hu R; Spofford LS; Aplin AE
Oncogene; 2007 Feb; 26(7):1056-66. PubMed ID: 16924241
[TBL] [Abstract][Full Text] [Related]
4. CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover: an independent prognosticator with potential p27 (Kip1)-independent oncogenic attributes?
Huang CW; Lin CY; Huang HY; Liu HW; Chen YJ; Shih DF; Chen HY; Juan CC; Ker CG; Huang CY; Li CF; Shiue YL
Ann Surg Oncol; 2010 Mar; 17(3):907-22. PubMed ID: 19866239
[TBL] [Abstract][Full Text] [Related]
5. Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1).
Zhao Y; Tang Q; Ni R; Huang X; Wang Y; Lu C; Shen A; Wang Y; Li C; Yuan Q; Chen H; Cheng C; He S
Hum Pathol; 2013 Mar; 44(3):365-73. PubMed ID: 22995332
[TBL] [Abstract][Full Text] [Related]
6. EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation.
Mo SJ; Hou X; Hao XY; Cai JP; Liu X; Chen W; Chen D; Yin XY
Cancer Commun (Lond); 2018 Apr; 38(1):9. PubMed ID: 29764501
[TBL] [Abstract][Full Text] [Related]
7. Cks1 regulates human hepatocellular carcinoma cell progression through osteopontin expression.
Kang YS; Jeong EJ; Seok HJ; Kim SK; Hwang JS; Choi ML; Jo DG; Kim Y; Choi J; Lee YJ; Jung E; Min JK; Han TS; Kim JS
Biochem Biophys Res Commun; 2019 Jan; 508(1):275-281. PubMed ID: 30497779
[TBL] [Abstract][Full Text] [Related]
8. URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway.
Xing S; Zhang B; Hua R; Tai WC; Zeng Z; Xie B; Huang C; Xue J; Xiong S; Yang J; Liu S; Li H
BMC Cancer; 2015 May; 15():368. PubMed ID: 25947641
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of Cks1 and Skp2 with TNFα/NF-κB signaling in chronic progressive nephropathy.
Suzuki S; Fukasawa H; Misaki T; Togawa A; Ohashi N; Kitagawa K; Kotake Y; Niida H; Hishida A; Yamamoto T; Kitagawa M
Genes Cells; 2011 Nov; 16(11):1110-20. PubMed ID: 22017545
[TBL] [Abstract][Full Text] [Related]
10. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β.
Li HP; Zeng XC; Zhang B; Long JT; Zhou B; Tan GS; Zeng WX; Chen W; Yang JY
Carcinogenesis; 2013 Nov; 34(11):2443-51. PubMed ID: 23740840
[TBL] [Abstract][Full Text] [Related]
11. p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
Zhao H; Lu Z; Bauzon F; Fu H; Cui J; Locker J; Zhu L
Oncogene; 2017 Jan; 36(1):60-70. PubMed ID: 27181203
[TBL] [Abstract][Full Text] [Related]
12. Role of Cks1 overexpression in oral squamous cell carcinomas: cooperation with Skp2 in promoting p27 degradation.
Kitajima S; Kudo Y; Ogawa I; Bashir T; Kitagawa M; Miyauchi M; Pagano M; Takata T
Am J Pathol; 2004 Dec; 165(6):2147-55. PubMed ID: 15579456
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.
Uehara N; Yoshizawa K; Tsubura A
Oncol Rep; 2012 Jul; 28(1):105-10. PubMed ID: 22484732
[TBL] [Abstract][Full Text] [Related]
14. Silencing of KIF14 interferes with cell cycle progression and cytokinesis by blocking the p27(Kip1) ubiquitination pathway in hepatocellular carcinoma.
Xu H; Choe C; Shin SH; Park SW; Kim HS; Jung SH; Yim SH; Kim TM; Chung YJ
Exp Mol Med; 2014 May; 46(5):e97. PubMed ID: 24854087
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor upregulates Skp2/Cks1 and p27(kip1) in human extrahepatic cholangiocarcinoma cells.
Kim JY; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim DH; Chae SW; Sohn JH
World J Gastroenterol; 2014 Jan; 20(3):755-73. PubMed ID: 24574749
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
[TBL] [Abstract][Full Text] [Related]
17. Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression.
Halfter H; Friedrich M; Resch A; Kullmann M; Stögbauer F; Ringelstein EB; Hengst L
Cancer Res; 2006 Jul; 66(13):6530-9. PubMed ID: 16818624
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma.
Shen DY; Fang ZX; You P; Liu PG; Wang F; Huang CL; Yao XB; Chen ZX; Zhang ZY
Liver Int; 2010 Jan; 30(1):119-25. PubMed ID: 19845855
[TBL] [Abstract][Full Text] [Related]
19. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.
Ozaki I; Zhang H; Mizuta T; Ide Y; Eguchi Y; Yasutake T; Sakamaki T; Pestell RG; Yamamoto K
Clin Cancer Res; 2007 Apr; 13(7):2236-45. PubMed ID: 17404108
[TBL] [Abstract][Full Text] [Related]
20. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
Old JB; Kratzat S; Hoellein A; Graf S; Nilsson JA; Nilsson L; Nakayama KI; Peschel C; Cleveland JL; Keller UB
Mol Cancer Res; 2010 Mar; 8(3):353-62. PubMed ID: 20197382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
